GeoVax Labs has developed a modified vaccinia Ankara (MVA) vector to generate an immune response against hemorrhagic fever viruses like ebolavirus, Marburgvirus, and arenavirus. The vector encodes specific viral antigens, offering both prophylactic and therapeutic benefits in preventing and treating infections caused by these deadly viruses. GlobalData’s report on GeoVax Labs gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights GeoVax Labs Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on GeoVax Labs, was a key innovation area identified from patents. GeoVax Labs's grant share as of February 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.

Recombinant mva vector for generating immune response to hemorrhagic viruses

Source: United States Patent and Trademark Office (USPTO). Credit: GeoVax Labs Inc

A recently granted patent (Publication Number: US11896657B2) discloses a recombinant modified vaccinia ankara (MVA) vector designed to express Marburg virus (MARV) glycoprotein and VP40 matrix protein. The vector includes specific nucleic acid sequences under the control of promoters compatible with poxvirus expression systems, strategically located within the MVA genome to facilitate the assembly of virus-like particles (VLPs) when expressed in a host cell. The optimization of the nucleic acid sequences is achieved through codon changes, interruption of homopolymer stretches, and transcription terminator motifs using silent mutations, enhancing protein expression by MVA.

Furthermore, the patent details the specific nucleic acid sequences encoding MARV glycoprotein and VP40 matrix protein, derived from the same MARV strain, and their precise locations within the MVA genome. The recombinant MVA vector, along with the expressed proteins, has the potential to form VLPs, which could have implications in vaccine development against Marburg virus. Additionally, the patent includes claims for pharmaceutical compositions comprising the recombinant MVA vector and a pharmaceutically acceptable carrier, indicating potential applications in the development of therapeutic interventions against MARV infection.

To know more about GlobalData’s detailed insights on GeoVax Labs, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies